Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/ijms24098187
Keywords
infliximab; adalimumab; etanercept; certolizumab pegol; golimumab; autoimmune diseases; inflammatory bowel disease; paradoxical reactions
Ask authors/readers for more resources
Anti-tumour necrosis factor (TNF)-a agents are increasingly used for treating inflammatory bowel disease and various inflammatory disorders. However, the use of these drugs can sometimes lead to paradoxical reactions, which are still not well understood. In this study, we discuss the clinical aspects and overall outcomes of autoimmune diseases caused by anti-TNF-a therapies.
Anti-tumour necrosis factor (TNF)-a agents have been increasingly used to treat patients affected by inflammatory bowel disease and dermatological and rheumatologic inflammatory disorders. However, the widening use of biologics is related to a new class of adverse events called paradoxical reactions. Its pathogenesis remains unclear, but it is suggested that cytokine remodulation in predisposed individuals can lead to the inflammatory process. Here, we dissect the clinical aspects and overall outcomes of autoimmune diseases caused by anti-TNF-a therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available